Epidermal growth factor receptor tyrosine kinase inhibitor rechallenge after epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease: report of one case and review of literature
Objective: To explore the clinical feasibility of successfully reusing similar drugs after the improvement of interstitial pneumonia (ILD) caused by epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Method: A retrospective analysis was conducted on the clinical data of a lung adenocarcinoma patient treated with gefitinib and successfully treated with similar drugs after improvement in ILD at Beijing Tsinghua Changgeng Hospital, and literature review was conducted. The result was a 53 year old male patient who developed wheezing after 50 days of treatment with gefitinib for metastatic lung adenocarcinoma. Combined with lung CT and blood gas analysis, the diagnosis was EGFR-TKI related ILD. Targeted drugs were discontinued and hormone therapy was given. After significant improvement in symptoms, similar drugs were administered again, and the tumor was controlled without any further occurrence of ILD. Conclusion: After the improvement of ILD symptoms caused by EGFR-TKI, with the patient's informed consent and close monitoring, similar drugs can be tried again in clinical practice, which can prolong the patient's survival period.